Associations - EGFR mutation + KRAS mutation

BIOMARKER:

EGFR mutation + KRAS mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Colorectal Cancer CRC	cetuximab Resistant: D – Preclinical cetuximab Resistant : D